Female Health FHCO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Female Health FHCO

VERU 2.965

-1.5%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	9/14/2022 2:52:40 PM
	of 211

Canadian pharmaceutical company Valeo Pharma Inc. said Wednesday it has entered a commercial services agreement with Veru Inc. for the Covid-19 treatment, sabizabulin, in Canada. Valeo said sabizabulin is a antiviral and anti-inflammatory agent aimed to treat hospitalized patients with moderate-to-severe Covid-19 who are at a high risk for acute respiratory distress syndrome and death. Veru submitted a request for emergency-use authorization to the U.S. Food and Drug Administration, and will be working with Health Canada as well to submit its application there. Write to Adriano Marchese at adriano.marchese@wsj.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next